https://peptidesciencedaily.com Independent, cited reporting on peptide research, trials, regulation, and safety. Not medical advice. en Wed, 01 Jul 2026 09:00:00 GMT https://peptidesciencedaily.com/news/fda-advisory-committee-503a-peptides-july-2026 https://peptidesciencedaily.com/news/fda-advisory-committee-503a-peptides-july-2026 Wed, 01 Jul 2026 09:00:00 GMT The Pharmacy Compounding Advisory Committee is scheduled to review seven peptides for the Section 503A bulk drug substances list on July 23-24, part of a broader reconsideration of substances the agency flagged in 2023. https://peptidesciencedaily.com/research/retatrutide-phase-2-triple-agonist-obesity-trial https://peptidesciencedaily.com/research/retatrutide-phase-2-triple-agonist-obesity-trial Wed, 01 Jul 2026 09:00:00 GMT A single investigational molecule engages three metabolic hormone receptors at once. Here is what the New England Journal of Medicine data actually showed, and what it does not. https://peptidesciencedaily.com/news/fda-scientists-question-peptides-rfk-ahead-of-panel-july-2026 https://peptidesciencedaily.com/news/fda-scientists-question-peptides-rfk-ahead-of-panel-july-2026 Wed, 01 Jul 2026 09:00:00 GMT Career reviewers at the agency posted documents finding little human evidence for BPC-157, TB-500 and five other peptides, setting up a clash with Health Secretary Robert F. Kennedy Jr., who has pushed to widen access before the July 23-24 advisory meeting. https://peptidesciencedaily.com/news/tga-schedules-bpc-157-prescription-only-australia https://peptidesciencedaily.com/news/tga-schedules-bpc-157-prescription-only-australia Sat, 27 Jun 2026 09:00:00 GMT A TGA decision added the experimental peptide BPC-157 to Schedule 4 of the Poisons Standard effective June 1, 2024, amid warnings about a growing market for unapproved peptide products. https://peptidesciencedaily.com/research/select-trial-semaglutide-cardiovascular-outcomes https://peptidesciencedaily.com/research/select-trial-semaglutide-cardiovascular-outcomes Wed, 24 Jun 2026 09:00:00 GMT A landmark outcomes study asked whether a GLP-1 peptide prevents heart attacks and strokes, not just weight. The 17,604-person answer reshaped how the class is viewed. https://peptidesciencedaily.com/news/novo-nordisk-cagrisema-fda-filing-obesity https://peptidesciencedaily.com/news/novo-nordisk-cagrisema-fda-filing-obesity Sat, 20 Jun 2026 09:00:00 GMT The company submitted a New Drug Application on December 18, 2025 for the once-weekly injection combining semaglutide and the amylin analogue cagrilintide for chronic weight management. https://peptidesciencedaily.com/research/surmount-1-tirzepatide-obesity-trial https://peptidesciencedaily.com/research/surmount-1-tirzepatide-obesity-trial Wed, 17 Jun 2026 09:00:00 GMT The pivotal obesity trial for tirzepatide reset expectations for what a single injectable peptide could achieve. A look at the actual numbers, endpoints, and caveats. https://peptidesciencedaily.com/news/fda-approves-wegovy-semaglutide-mash-liver-fibrosis https://peptidesciencedaily.com/news/fda-approves-wegovy-semaglutide-mash-liver-fibrosis Fri, 12 Jun 2026 09:00:00 GMT The August 15, 2025 decision made semaglutide 2.4 mg the first GLP-1 receptor agonist cleared to treat noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis. https://peptidesciencedaily.com/news/retatrutide-triumph-1-phase-3-obesity-results https://peptidesciencedaily.com/news/retatrutide-triumph-1-phase-3-obesity-results Thu, 21 May 2026 09:00:00 GMT Topline results from TRIUMPH-1, the first pivotal trial of the investigational triple-hormone agonist, showed average weight reductions of roughly 19% to 28% across three doses over 80 weeks.